BBA
ITOS

Baker Bros. Advisors’s iTeos Therapeutics ITOS Stock Holding History

Baker Bros. Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150,346
Closed -$1.65M – 94
2023
Q3 		$1.65M Hold
150,346
– – 0.01% 90
2023
Q2 		$1.99M Hold
150,346
– – 0.01% 96
2023
Q1 		$2.05M Hold
150,346
– – 0.01% 90
2022
Q4 		$2.94M Hold
150,346
– – 0.02% 88
2022
Q3 		$2.86M Hold
150,346
– – 0.02% 93
2022
Q2 		$3.1M Hold
150,346
– – 0.02% 89
2022
Q1 		$4.84M Hold
150,346
– – 0.03% 86
2021
Q4 		$7M Hold
150,346
– – 0.03% 86
2021
Q3 		$4.06M Hold
150,346
– – 0.02% 102
2021
Q2 		$3.86M Hold
150,346
– – 0.02% 101
2021
Q1 		$5.14M Hold
150,346
– – 0.02% 93
2020
Q4 		$5.08M Sell
150,346
-17,216
-10% -$456K 0.02% 91
2020
Q3 		$4.13M Buy
+167,562
New +$4.51M 0.02% 84

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Baker Bros. Advisors's ITOS Position: Q4 2023 in Review

Baker Bros. Advisors sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 150,346 shares — an estimated $1.65M sold.

Baker Bros. Advisors first reported a position in ITOS in Q3 2020 and held it in 13 quarters. The position peaked at $7M in Q4 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Baker Bros. Advisors reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 150,346 iTeos Therapeutics shares in Q4 2023, an estimated $1.65M.
  • Baker Bros. Advisors first reported a position in iTeos Therapeutics in Q3 2020 and held it in 13 quarters.
  • Baker Bros. Advisors's iTeos Therapeutics position peaked at $7M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.